December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Enrique Grande: Couldn’t find a better host like Carolina Ibanez and a better partner in crime than Shilpa Gupta
Nov 26, 2024, 17:35

Enrique Grande: Couldn’t find a better host like Carolina Ibanez and a better partner in crime than Shilpa Gupta

Enrique Grande, the Head of Oncology at MD Anderson Cancer Center Madrid, shared a post on X:

“Couldn’t find a better host like Carolina Ibanez not a better partner in crime than Shilpa Gupta.

GU field is fun!

Thanks to the Catholic University and German Clinic for hosting this meeting.”

Shilpa Gupta, Director of Genitourinary Oncology, shared this post qouting:

“Agree with Enrique Grande.

Thanks Carolina Ibanez, Cristobal Sanhueza Condell for such a high impact Uroonc meeting at Catholic University, German Clinic.

Enjoyed all the sessions covering latest data in GU cancers. Unmet need to address disparities in access to cancer meds in rest of the world.

Special thanks for your warm and kind hospitality!”

More posts featuring Enrique Grande and Shilpa Gupta.

Enrique Grande, MD, PhD, MSc, is the Head of Oncology at MD Anderson Cancer Center Madrid, and an Associate Professor at Francisco de Vitoria University. He is also an Adjunct Professor at the GU Medical Oncology Department.
Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit.

He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE).

Dr. Grande edits several international journals and has participated in recent neuroendocrine tumor trials that led to the approval of new drugs in this field.

Dr. Shilpa Gupta is the Director of Genitourinary Oncology, a staff member in Hematology and Oncology and a Professor of Medicine at Cleveland Clinic. Dr. Gupta’s extensive research focuses on novel drug development and biomarkers of response/resistance in bladder cancer, contributing to numerous published works and leadership roles in clinical trials.